Unlocking the therapeutic potential of natural compounds
Nanyang Biologics’ AI-driven DTIGN platform analyzes molecules derived from natural compounds to discover their effects on the human body. But this resource-intensive platform requires powerful GPUs and high-performance connectivity to efficiently screen a library of two billion plant-derived compounds and accurately predict their bioactivities to accelerate drug discovery.
Learn how Nanyang Biologics leveraged Equinix’s Distributed AI architecture to accelerate drug discovery by 68%, cut R&D costs by 90%, and harness data gravity for DTIGN — unlocking nature’s insights through the power of AI.
We aim to be the platform of choice for people looking to discover compounds for drugs and other uses. Scanning natural compound data requires powerful GPUs that consume a lot of energy. That’s why we want to collaborate with organizations like HPE, NVIDIA and Equinix, who have extensive experience in developing and running data centers, scaling GPUs and managing IT operations.
Giang Nguyen
CTO, Nanyang Biologics